Gwynn Pardee
Novartis (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Synthesis and biological activity, Protein Kinase Regulation and GTPase Signaling, Cytokine Signaling Pathways and Interactions, Cancer Mechanisms and Therapy
Most-Cited Works
- → Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo(2014)724 cited
- → LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors(2020)84 cited
- → Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors(2017)40 cited
- → Baculovirus-driven protein expression in insect cells: A benchmarking study(2018)34 cited
- → Inhibition of prenylated KRAS in a lipid environment(2017)31 cited
- Soluble IL-2 receptor beta and gamma subunits: ligand binding and cooperativity.(1994)
- → Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon(2023)17 cited
- → In-Depth Characterization and Validation in BRG1 -Mutant Lung Cancers Define Novel Catalytic Inhibitors of SWI/SNF Chromatin Remodeling(2019)9 cited
- → Identification of Brain-Penetrant ATP-Competitive mTOR Inhibitors for CNS Syndromes(2023)3 cited
- → Binding Rate Screen – A high-throughput assay in soluble lysate for prioritizing protein expression constructs(2009)1 cited